

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

DePaoli 1



Section 1. Identifying Inform	nation					
1. Given Name (First Name) Alex	2. Surname (Last Name) DePaoli 3. Date 20-January-2021					
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Lei Ling				
5. Manuscript Title Potent Suppression of Hydrophobic Bile Acids by Aldafermin, an FGF19 Analogue, Across Metabolic and Cholestatic Liver Diseases						
6. Manuscript Identifying Number (if you k JHEPR-D-21-00016R1	now it)	_				
Section 2. The Week Under Co	onsideration for Publi					
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,				
Section 3. Relevant financial	activities outside the	submitted work.				
of compensation) with entities as descr	ibed in the instructions. U	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.				
Are there any relevant conflicts of inter						
If yes, please fill out the appropriate inf	ormation below.					
Name of Entity	Grant	n-Financial Other? Comments				
NGM Biopharmaceuticals		employee and stockholder				
Section 4. Intellectual Prope	rty Patents & Copyri	ghts				
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work? Yes V No				

DePaoli 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. DePaoli reports other from NGM Biopharmaceuticals, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

DePaoli 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation					
1. Given Name (First Name) Arun	2. Surname Sanyal	e (Last Nan	ne)		3. Date 20-January-2021	
4. Are you the corresponding author?	Yes	√ No	Correspond Lei Ling	or's Name		
 Manuscript Title Potent Suppression of Hydrophobic Bile Diseases 	Acids by Al	ldafermin	ı, an FGF19 Analo	gue, Acro	oss Metabolic and Cholestatic Liver	
6. Manuscript Identifying Number (if you know JHEPR-D-21-00016R1	ow it)					
Section 2. The Work Under Co		f D	uh Bandian			
						٠. ٢
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)?						c.) for
Are there any relevant conflicts of intere	st? Ye	es 🗸 l	No			
Section 3. Relevant financial a	ctivities c	outside t	the submitted	work.		
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest of the second	oed in the ir ort relation st?	nstructior ships that s I	ns. Use one line fo	r each er	ntity; add as many lines as you need	
Name of Entity	Grant? P	ersonal Fees	Non-Financial Support?	Other?	Comments	
Gilead,			Баррогс	√	consultant	
Allergan				✓	consultant	
Bristol-Myers Squibb				✓	consultant	
Pfizer				✓	consultant	
Merck				✓	consultant	
Galmed				✓	consultant	
Novartis				✓	consultant	
Novo Nordisk				✓	consultant	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Lilly				✓	consultant
Siemens				✓	consultant
Genentech				✓	consultant
Boehringer Ingelhiem				✓	consultant
Glympse Bio				✓	consultant
Genfit				\checkmark	consultant
Coherus				✓	consultant
Surrozen				\checkmark	consultant
Poxel				✓	consultant
89 Bio				✓	consultant
Perspectum				✓	consultant
AstraZeneca				✓	consultant
Medimmune				✓	consultant
Lipocine				✓	consultant
Indalo,				✓	own stock options
Durect				✓	own stock options
Tiziana				✓	own stock options
Exhalenz				✓	own stock options
Northsea				✓	own stock options

Section 4.	Intellectual Property Patents & Copyrights
Do you have an	y patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Sanyal reports other from Gilead, , other from Allergan, other from Bristol-Myers Squibb, other from Pfizer, other from Merck, other from Galmed, other from Novartis, other from Novo Nordisk, other from Lilly, other from Siemens, other from Genentech, other from Boehringer Ingelhiem, other from Glympse Bio, other from Genfit, other from Coherus, other from Surrozen, other from Poxel, other from 89 Bio, other from Perspectum, other from AstraZeneca, other from Medimmune, other from Lipocine, other from Indalo, , other from Durect, other from Tiziana, other from Exhalenz, other from Northsea, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	untion.								
1. Given Name (First Name) Gideon	2. Surname (Last Name) Hirschfield		3. Date 20-January-2021						
4. Are you the corresponding author?	Yes ✓ No	Correspondii Lei Ling	esponding Author's Name						
5. Manuscript Title Potent Suppression of Hydrophobic Bil Diseases	le Acids by Aldafermin, ar	n FGF19 Analog	ue, Across Metabolic and Cholestat	ic Liver					
6. Manuscript Identifying Number (if you know it) JHEPR-D-21-00016R1									
Continue									
Section 2. The Work Under C	onsideration for Pub	lication							
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, o								
Section 3. Relevant financial	activities outside the	submitted w	ork.						
Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should re Are there any relevant conflicts of inter If yes, please fill out the appropriate inf	ribed in the instructions. It port relationships that we rest?	Jse one line for	each entity; add as many lines as y	ou need by					
Name of Entity	Grant? Personal No	on-Financial Support	Other? Comments						
Cymabay			✓ consulting						
Genfit			✓ consulting						
Falk			✓ consulting						
Intercept			✓ consulting						
GSK			✓ consulting						
Mirum			✓ consulting						
Roche			✓ consulting						
Pliant			consulting						



Name of Entity	Grant? Persona	I Non-Financial Support?	Other?	Comments		
Section 4. Intellectual Propert	ty Patonts & Co	anyriahts				
ıntenectuai Propert	ly Patents & Co	ppyrights				
Do you have any patents, whether plann	ed, pending or issu	ied, broadly releva	nt to the	work? Yes No		
Section 5. Relationships not o	overed above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conc	litions/circumstanc	es are present (ex	plain belo	w):		
No other relationships/conditions/ci	rcumstances that p	resent a potential	conflict of	interest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.	n will automatically	generate a disclo	sure state	ment, which will appear in the box		
Dr. Hirschfield reports other from Cymal from Mirum, other from Roche, other fro the submitted work; .						



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Lieu 1



Section 1.	Identifying Inform	nation					
1. Given Name (Fi Hsiao	rst Name)	2. Surname Lieu	e (Last Name)		3. Date 20-January-2021		
4. Are you the cor	responding author?	Yes	nor's Name				
5. Manuscript Title Potent Suppression of Hydrophobic Bile Acids by Aldafermin, an FGF19 Analogue, Across Metabolic and Cholestatic Liver Diseases							
· · · · · · · · · · · · · · · · · · ·	. Manuscript Identifying Number (if you know it) HEPR-D-21-00016R1						
Section 2.	The Work Under C	onsideratio	on for Publi	cation			
any aspect of the s statistical analysis, Are there any rel	submitted work (including	but not limite	ed to grants, d		nent, commercial, private foundation, etc.) for study design, manuscript preparation,		
Section 3.	Relevant financial	activities o	outside the	submitted work.			
of compensation	n) with entities as descri	ibed in the ir	nstructions. U	se one line for each e	ncial relationships (regardless of amount entity; add as many lines as you need by ne 36 months prior to publication.		
Are there any rel	evant conflicts of intere	est? ✓ Ye	es No				
If yes, please fill o	out the appropriate info	ormation bel	low.				
Name of Entity		Grant?	-	n-Financial Support?	Comments		
NGM Biopharmaceut	ticals				employee and stockholder		
Coation A							
Section 4.	Intellectual Proper	rty Paten	ts & Copyri	ghts			
Do you have any	patents, whether plan	ned, pendin	g or issued, b	roadly relevant to the	e work? ☐ Yes ✓ No		

Lieu 2



Section 5. Polotionships not solvered above						
Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):						
✓ No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Statement						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Lieu reports other from NGM Biopharmaceuticals, outside the submitted work; .						

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lieu 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Ling 1



Section 1.	Identifying Inform	ation						
1. Given Name (Fi Lei				3. Date 20-January-2021				
4. Are you the cor	corresponding author? Yes No							
5. Manuscript Title Potent Suppression of Hydrophobic Bile Acids by Aldafermin, an FGF19 Analogue, Across Metabolic and Cholestatic Liver Diseases								
· · · · · · · · · · · · · · · · · · ·	6. Manuscript Identifying Number (if you know it) JHEPR-D-21-00016R1							
Section 2.	The Work Under Co	onsideration for P	ublication					
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to gran	ts, data monitoring		mmercial, private foundation, er sign, manuscript preparation,	c.) for		
Section 3.	Relevant financial	activities outside t	:he submitted v	work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication .								
Are there any rel	evant conflicts of intere	est? ✓ Yes	No					
If yes, please fill o	out the appropriate info	ormation below.						
Name of Entity		Grant? Personal Fees?	Non-Financial Support?	Other? Con	nments			
NGM Biopharmaceut	icals			✓ emplo	oyee and stockholder			
Section 4.	Intellectual Proper	ty Patents & Coր	oyrights					
Do you have any	patents, whether plan	ned, pending or issue	d, broadly releva	nt to the work?	Yes ✓ No			

Ling 2



Section 5. Polationships not savared above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Ling reports other from NGM Biopharmaceuticals, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ling 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Harrison 1



Section 1. Identifying Info	ormation		l.			
1. Given Name (First Name) Stephen	2. Surname (Last Nar Harrison	me)	3. Date 20-January-2021			
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Lei Ling	Corresponding Author's Name Lei Ling			
5. Manuscript Title Potent Suppression of Hydrophobic Diseases	: Bile Acids by Aldafermir	n, an FGF19 Analogue	e, Across Metabolic and Cholestatic Liver			
6. Manuscript Identifying Number (if yo JHEPR-D-21-00016R1	u know it)					
Section 2. The Work Unde	r Consideration for P	ublication				
Place a check in the appropriate box of compensation) with entities as de	ial activities outside res in the table to indicat escribed in the instruction dreport relationships tha	e whether you have t ns. Use one line for ea	rk. financial relationships (regardless of amou ach entity; add as many lines as you need ng the 36 months prior to publication.			
If yes, please fill out the appropriate	information below.					
Name of Entity	Grant? Personal Fees?	Non-Financial Ot	her? Comments			
Conatus			✓ research support			
Galectin			research support, consulting advisor			
Galmed			research support, consulting advisor			
Genfit			research support, consulting advisor			
Gilead			✓ consulting advisor, research support			
Intercept			research support, consulting advisor			
Madrigal			✓ research support, consulting advisor			

Harrison 2

research support, consulting advisor

NGM



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Akero				√	research support, consulting advisor
Axcella				√	research support, consulting advisor
Metacrine				√	research support, consulting advisor
Sagimet				√	research support, consulting advisor
Enyo				√	research support
NorthSea				√	research support
Genentech				√	research support
Hepion				√	research support
Cymabay				√	research support
Hightide				√	research support, consulting advisor
Chronic Liver Disease Foundation				√	consulting advisor
Cirius				√	consulting advisor
Echosens				√	consulting advisor
Perspectum				√	consulting advisor
Medpace				√	consulting advisor
Blade				✓	consulting advisor
Viking				√	consulting advisor
Poxel				√	consulting advisor
Terns				√	consulting advisor
HistoIndex				√	consulting advisor
Hepion				✓	consulting advisor
Ridgeline Therapeutics				✓	consulting advisor
ZiVi				✓	consulting advisor
Prometic				√	consulting advisor

Section 4.	Intellectual Property Patents & Copyrights	
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work?	✓ No

Harrison 3



Section 5.	Relationships not covered above							
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?							
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):							
✓ No other rela	No other relationships/conditions/circumstances that present a potential conflict of interest							
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.							
Section 6.	Disclosure Statement							
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box							

Dr. Harrison reports other from Conatus, other from Galectin, other from Galmed, other from Genfit, other from Gilead, other from Intercept, other from Madrigal, other from NGM, other from Akero, other from Axcella, other from Metacrine, other from Sagimet, other from Enyo, other from NorthSea, other from Genentech, other from Hepion, other from Cymabay, other from Hightide, other from Chronic Liver Disease Foundation, other from Cirius, other from Echosens, other from Perspectum, other from Medpace, other from Blade, other from Viking, other from Poxel, other from Terns, other from Histolndex, other from Hepion, other from Ridgeline Therapeutics, other from CiVi, other from Prometic, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Harrison 4



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1.	Identifying Inform	ation						
1. Given Name (Fi Ulrich	2. Surnar Beuers	ne (Last Nan	ne)	3. Date 20-January-2021				
4. Are you the cor	responding author?	Yes	Yes No Correspondir			ling Author's Name		
5. Manuscript Title Potent Suppress Diseases		Acids by	Aldafermin	ı, an FGF19 Analo	gue, Acro	oss Metabolic and Cholestatic Liver		
6. Manuscript Ider JHEPR-D-21-000	ntifying Number (if you kn 16R1	ow it)						
	l							
Section 2.	The Work Under Co	onsiderat	tion for P	ublication				
any aspect of the s statistical analysis,	ubmitted work (including	but not lim	nited to gran			ent, commercial, private foundation, etc.) udy design, manuscript preparation,	TOT	
Section 3.	Relevant financial	activities	outside t	the submitted	work.			
of compensation clicking the "Add Are there any rele) with entities as descri	bed in the port relationst?	instruction onships tha Yes	ns. Use one line fo	or each er	cial relationships (regardless of amountity; add as many lines as you need be a 36 months prior to publication .		
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
ntercept					√	consulting, lecture fees, research support	_	
Novartis					✓	consulting, lecture fees		
PSC patient foundation	ons	✓						
Abbvie					✓	lecture fees		
Falk Foundation					✓	lecture fees, research support		
Gilead					✓	lecture fees		
Roche					1	lecture fees		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Shire			Зиррогс	✓	lecture fees	
Zambon				✓	lecture fees	
Section 4. Intellectual Branch						
Intellectual Propert	y Pater	nts & Cop	oyrights			
Do you have any patents, whether plann	ed, pendir	ng or issue	ed, broadly releva	nt to the	work? Yes No	
Section 5. Relationships not o	overed a	bove				
Are there other relationships or activities				influence	d, or that give the appearance of	
potentially influencing, what you wrote i	in the subn	nitted wo	rk?			
Yes, the following relationships/conc	ditions/circ	umstance	s are present (exp	olain belo	w):	
✓ No other relationships/conditions/cir	rcumstance	es that pre	esent a potential o	conflict o	finterest	
At the time of manuscript acceptance, jo	ournals will	ask autho	ors to confirm and	d, if neces	sary, update their disclosure statemer	nts.
On occasion, journals may ask authors to						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form	n will autor	matically (generate a disclos	sure state	ment, which will appear in the box	
below.						
Dr. Beuers reports other from Intercept, from Falk Foundation, other from Gileac						
work; .	i, other mor	in noche,	other morn stille,	other no	m Zambon, oddade the sabinited	
						_



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.